Rare Conversations 2022!
Managing uncertainties in rare disease innovation Joins us for the new episode of Rare Conversations 2022! The second episode of Rare Conversations 2022 will build on […]
Managing uncertainties in rare disease innovation Joins us for the new episode of Rare Conversations 2022! The second episode of Rare Conversations 2022 will build on […]
Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients, both in terms of innovative treatments, but also via use of innovative prevention, […]
EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient organisations and the biopharmaceutical industry. […]
Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient's lives and their families...
The development of therapies (OMPs) for rare diseases comes with distinct challenges, including patient recruitment, setting meaningful clinical endpoints, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy.
From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension, the challenges in EU healthcare and pharmaceutical policy are ever-evolving.
In April 2023, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem.
Held annually since 2004, the TOPRA Symposium is Europe’s premier conference for healthcare regulatory affairs. With dedicated programme streams for human medicines, medical devices and IVDs, and veterinary medicines, the Symposium is the must-attend event in the regulatory affairs calendar.
The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.
This panel will discuss what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.
Hybrid Event | Invitation Only EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient […]
The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium.